Two studies investigated the effect of atorvastatin on glycaemic control and renal function in patients with type 2 diabetes. In study 1, 27 outpatients with hypercholesterolaemia (16 statin-naïve, 11 switched from another statin) took atorvastatin (10 mg once daily) for 3 months. After 3 months, low-density lipoprotein cholesterol (LDL-C) had decreased significantly in both groups, high-density lipoprotein cholesterol (HDL-C) and estimated glomerular filtration rate had increased only in the statin-naïve group, and glycosylated haemoglobin (HbA1c) had not changed significantly in either group. Study 2 was a retrospective investigation of 87 outpatients with hyper cholesterolaemia who had been taking atorvastatin for at least 4 years. Compared with baseline (patients who had taken atorvastatin for at least 1 year), total cholesterol and triglyceride levels did not change over the study period, HDL-C increased significantly at 2 and 3 years, HbA1c was significantly decreased at 1, 2 and 3 years and serum creatinine was significantly decreased at 1 year. Atorvastatin lowered LDL-C concentration, did not worsen glycaemic control and might improve renal function in patients with type 2 diabetes.
HaffnerSMLehtoSRonnemaaT: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998; 339: 229–234.
2.
StamlerJVaccaroONeatonJD: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care1993; 16: 434–444.
3.
WannametheeGWhincupPHShaperAG: Factors determining case fatality in myocardial infarction “who dies in a heart attack”?Br Heart J1995; 74: 324–331.
4.
HoJEPaultreFMoscaL: Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke2003; 34: 2812–2816.
5.
de JongGvan RaakLKesselsF: Stroke subtype and mortality: A follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol2003; 56: 262–268.
6.
NakamuraHArakawaKItakuraH: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study). Lancet2006; 368: 1155–1163.
7.
ShepherdJBarterPCarmenaR: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006; 29: 1220–1226.
8.
SeverPSPoulterNRDahlofB: Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care2005; 28: 1151–1157.
9.
AthyrosVGPapageorgiouAAMercourisBR: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin2002; 18: 220–228.
10.
ColhounHMBetteridgeDJDuttingtonPN: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet2004; 364: 685–696.
11.
DelahoyPJMaglianoDJWebbK: The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther2009; 31: 236–244.
12.
DouglasKO'MalleyPGJacksonJL: Meta-analysis: the effect of statins on albuminuria. Ann Intern Med2006; 145: 117–124.
13.
ShepherdJKasteleinJJPBittnerV: Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol2007; 2: 1131–1139.
14.
AthyrosVGMikhailidisDPPapageorgiouAA: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol2004; 57: 728–734.
15.
ColhounHMBetteridgeDJDurringtonPN: Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the collaborative atorvastatin diabetes study (CARDS). Am J Kidney Dis2009; 54: 810–819.
16.
VidtDGCressmanMDHarrisS: Rosuvastatin-induced arrest in progression of renal disease. Cardiology2004; 102: 52–60.
17.
KjekshusJApetreiEBarriosV: Rosuvastatin in older patients with systolic heart failure. N Engl J Med2007; 357: 2248–2261.
18.
SeverPSDahlofBPoulterNR: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet2003; 361: 1149–1158.
19.
KeechAColquhounDBestJ: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care2003; 26: 2713–2721.
20.
FreemanDJNorrieJSattarN: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation2001; 103: 357–362.
21.
CollinsRArmitageJ, ParishS for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet2003; 361: 2005–2016.
22.
RidkerPMDanielsonEFonsecaFA: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359: 2195–2207.
23.
TurnerRCMillnsHNeilHA: Risk factor for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ1998; 316: 823–828.
24.
RajpathakSNKumbhaniDJCrandallJ: Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care2009; 32: 1924–1929.
25.
SattarNPreissDMurrayHM: Statins and risk of incident diabetes: A collaborative meta-analysis of randomized statin trials. Lancet2010; 375: 735–742.
26.
StalenhoefAFBallantyneCMSartiC: A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J2005; 26: 2664–2672.
27.
YudkinJSRichterB: Intensive glucose control and cardiovascular outcomes. Lancet2009; 374: 522.
28.
KeithDSNicholsGAGullionCM: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med2004; 164: 659–663.
29.
KottgenARussellSDLoehrLR: Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol2007; 18: 1307–1315.
30.
IrieFIsoHSairenchiT: The relationship of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int2006; 69: 1264–1271.
31.
GersteinHCMannJFYiQ: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA2001; 286: 421–426.
32.
HillegeHLFidlerVDiercksGF: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation2002; 106: 1777–1782.
33.
AsselbergsFWDiercksGFHillegeHL: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004; 110: 2809–2816.
34.
de ZeeuwDRemuzziGParvingHH: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation2004; 110: 921–927.
35.
OlsenMHWachtellKIbsenH: Reduction in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens2006; 24: 775–781.
36.
SandhuSWiebeNFriedLF: Statins for improving renal outcomes: meta-analysis. J Am Soc Nephrol2006; 17: 2006–2016.
